Colinz Labs

Which are the latest news on Colinz Labs?

Why is Colinz Laboratories Ltd falling/rising?

As of 04-Aug, Colinz Laboratories Ltd's stock price is declining, currently at 78.00, reflecting a 0.55% decrease. Despite a strong year-to-date performance, recent trends show a significant downturn, with a 5.96% drop over the past week and decreased investor participation contributing to the stock's weakness.

As of 04-Aug, Colinz Laboratories Ltd's stock price is falling, currently at 78.00, which reflects a decrease of 0.43 or 0.55%. The stock has underperformed its sector by 0.5% today and has experienced a consecutive decline over the past two days, resulting in a total drop of 4.88% during this period. <BR><BR>In terms of recent performance, the stock has seen a significant decline of 5.96% over the past week, contrasting with a positive return of 2.17% for the Sensex. Although the stock has shown strong performance year-to-date with a gain of 45.44% compared to the Sensex's loss of 7.97%, the recent trend indicates a downturn. <BR><BR>Additionally, investor participation has decreased, as evidenced by the delivery volume on 03 Aug, which fell by 89.95% against the 5-day average. This decline in trading activity may contribute to the stock's downward pressure. Despite being above the 20-day, 50-day, 100-day, and 200-day moving averages, the stock is currently below the 5-day moving average, indicating a short-term weakness. Overall, these factors collectively explain the current decline in Colinz Laboratories Ltd's stock price.

Are Colinz Laboratories Ltd latest results good or bad?

Colinz Laboratories Ltd's latest results show a significant net profit increase of 1,311.76% to ₹2.40 crores, but this is largely due to extraordinary items rather than strong operational performance. Revenue fell 29.14% to ₹1.24 crores, raising concerns about sustainability and indicating underlying challenges, so investors should proceed with caution.

Colinz Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a significant net profit of ₹2.40 crores for Q1 FY27, which reflects an impressive increase of 1,311.76% quarter-on-quarter. However, this surge in profit appears to be driven by extraordinary items rather than strong operational performance.<BR><BR>In contrast, the company's revenue for the same quarter fell sharply to ₹1.24 crores, marking a decline of 29.14% from the previous quarter. This revenue contraction is concerning, especially as it also represents a year-on-year decrease of 21.02%. The operating profit margin has also decreased slightly to 4.84%, indicating challenges in maintaining profitability from core operations.<BR><BR>Furthermore, the substantial profit before tax figure of ₹2.90 crores raises questions about the sustainability of these earnings, as it seems disconnected from the lower revenue figures. The operational metrics suggest that the company is facing significant challenges, including a negative five-year sales growth and a notable reduction in promoter holding, which could indicate a lack of confidence in the company's future prospects.<BR><BR>Overall, while the headline profit figure looks good, the underlying operational difficulties and declining revenue suggest that the results are not as positive as they might initially seem. Investors should approach with caution and seek clarity on the nature of the profit surge before making any decisions.

Should I buy, sell or hold Colinz Laboratories Ltd?

When is the next results date for Colinz Laboratories Ltd?

The next results date for Colinz Laboratories Ltd is 30 July 2026.

The next results date for Colinz Laboratories Ltd is scheduled for 30 July 2026.

How big is Colinz Labs?

As of 10th June, Colinz Laboratories Ltd has a market capitalization of 15.00 Cr, with recent net sales of 6.14 Cr and a net profit of 0.51 Cr. Shareholder's funds are 9.47 Cr, and total assets amount to 11.82 Cr.

As of 10th June, Colinz Laboratories Ltd has a market capitalization of 15.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Colinz Laboratories Ltd reported Net Sales of 6.14 Cr and a Net Profit of 0.51 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 9.47 Cr and Total Assets of 11.82 Cr.

Who are in the management team of Colinz Labs?

The management team of Colinz Labs consists of L S Mani (Director & Company Secretary), N K Menon (Whole-time Director), Vasant K Bhat (Independent Director), and A Krishna Kumar (Independent Director).

The management team of Colinz Labs includes the following individuals:<BR><BR>1. L S Mani - Director & Company Secretary<BR>2. N K Menon - Whole-time Director<BR>3. Vasant K Bhat - Independent Director<BR>4. A Krishna Kumar - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Colinz Labs?

Colinz Labs' peers include Parmax Pharma, Desh Rakshak, Dipna Pharmachem, and others, with varying management and growth risks. Parmax Pharma leads in 1-year returns at 48.68%, while Colinz Labs has a return of -7.60%.

Peers: The peers of Colinz Labs are Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Starsource Multi, Zenith Health, Ortin Global, Beryl Drugs, Unjha Formul., and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Zenith Health, Ortin Global, Beryl Drugs, and the rest. Average management risk is found at Unjha Formul. and Saroja Pharma In. Excellent growth is noted at Dipna Pharmachem, while Below Average growth is seen at Parmax Pharma, Desh Rakshak, Zenith Health, Ortin Global, Beryl Drugs, and the rest. Average growth is present at Unjha Formul. and Saroja Pharma In. Good capital structure is noted at Zenith Health, Colinz Labs, and Unjha Formul., while Below Average capital structure is found at Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Ortin Global, Beryl Drugs, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Parmax Pharma at 48.68%, while the peer with the lowest is Dipna Pharmachem at -66.76%. Colinz Labs has a 1-year return of -7.60%, which is better than Dipna Pharmachem but worse than Parmax Pharma. Additionally, the six-month returns are negative for Dipna Pharmachem, Zenith Health, and Saroja Pharma In.

What does Colinz Labs do?

Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures various pharmaceutical formulations. As of March 2026, it reported net sales of 2 Cr and a market cap of INR 15 Cr.

Overview:<BR>Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures a wide variety of pharmaceutical formulations.<BR><BR>History:<BR>Colinz Laboratories Ltd was incorporated as a Private Limited Company in 1986 and converted into a Public Limited Company in 1995, the same year it commenced manufacturing and marketing activities. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 15 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.68 <BR>Return on Equity: 5.16% <BR>Price to Book: 1.50 <BR><BR>Contact Details:<BR>Address: A-101 Pratik Industrial Estate, Mulund Goregaon Link Road Mumbai Maharashtra : 400078 <BR>Tel: 91-022-25668002/8003 <BR>Email: colinzlabs@yahoo.com <BR>Website: http://www.cindoc-cll.in

Is Colinz Labs overvalued or undervalued?

As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.

As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics.<BR><BR>Despite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers.

How has been the historical performance of Colinz Labs?

Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.

Answer:<BR>The historical performance of Colinz Labs shows a fluctuating trend in net sales and profits over the years, with a slight decline in recent periods.<BR><BR>Breakdown:<BR>Colinz Labs reported net sales of 6.53 Cr in March 2025, down from 7.03 Cr in March 2024 and 7.15 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, remaining at 6.53 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased to 6.03 Cr in March 2025 from 6.49 Cr in March 2024. Operating profit (PBDIT) was 0.80 Cr in March 2025, slightly lower than 0.82 Cr in March 2024, while profit before tax was 0.62 Cr, down from 0.65 Cr the previous year. Profit after tax showed a modest increase to 0.50 Cr in March 2025 from 0.49 Cr in March 2024. The company's total assets rose to 11.82 Cr in March 2025 from 11.36 Cr in March 2024, and total liabilities also increased to 11.82 Cr from 11.36 Cr. Cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive inflow of 1.00 Cr in March 2024. Overall, while Colinz Labs has shown some resilience in profit margins, the decline in sales and cash flow raises concerns about its financial stability.

Who are the top shareholders of the Colinz Labs?

The top shareholder of Colinz Labs is Mani L S, holding 34.45% of the shares, with no pledged promoter holdings. The highest public shareholder is Dipakbhai Haribhai Gaudani at 1.31%, while individual investors collectively own 31.04%.

The top shareholders of Colinz Labs include the promoters, with Mani L S holding the largest share at 34.45%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Dipakbhai Haribhai Gaudani, who holds 1.31%. Additionally, individual investors collectively hold 31.04% of the shares.

What is the technical trend for Colinz Labs?

As of 26 May 2025, Colinz Labs shows a bullish technical trend supported by positive daily and weekly indicators, although caution is advised due to mildly bearish signals from the monthly MACD and Dow Theory.

As of 26 May 2025, the technical trend for Colinz Labs has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the upward momentum, while the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames, reinforcing the positive outlook. However, the monthly MACD and Dow Theory show mildly bearish signals, suggesting some caution. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish indicators on the daily and weekly charts.

Has Colinz Labs declared dividend?

No Dividend History Available